Birchview Capital, LP Alkermes Plc. Transaction History
Birchview Capital, LP
- $108 Million
- Q3 2024
A detailed history of Birchview Capital, LP transactions in Alkermes Plc. stock. As of the latest transaction made, Birchview Capital, LP holds 50,000 shares of ALKS stock, worth $1.45 Million. This represents 1.29% of its overall portfolio holdings.
Number of Shares
50,000
Previous 50,000
-0.0%
Holding current value
$1.45 Million
Previous $1.21 Million
16.1%
% of portfolio
1.29%
Previous 1.2%
Shares
2 transactions
Others Institutions Holding ALKS
# of Institutions
363Shares Held
181MCall Options Held
175KPut Options Held
96.6K-
Black Rock Inc. New York, NY29.1MShares$845 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA19MShares$551 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD13MShares$377 Million0.04% of portfolio
-
Wellington Management Group LLP Boston, MA12.7MShares$368 Million0.06% of portfolio
-
State Street Corp Boston, MA9.19MShares$267 Million0.01% of portfolio
About Alkermes plc.
- Ticker ALKS
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 164,254,000
- Market Cap $4.77B
- Description
- Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...